Antibody Bioengineered atbtherapeutics is a pioneering biopharmaceutical company building a new line of attack against cancer. atbtherapeutics has developed the atbody; a game-changer biologic format designed to broaden the therapeutic window of antibody-based therapies. Only our proprietary and versatile plant-based atbiofarm technology enables single-step manufacturing of our novel class of therapeutic atbodies. The resulting therapeutics offer a novel mechanism of action, avoiding major cancer cell resistance, and provide a promising, life-changing therapy for hard-to-treat and refractory cancer.

91 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Versatile immunotherapy for personalized cancer medicine Inovactis develops an innovative treatment against cancer at the border between several ongoing revolutions: individualized medicine, immunotherapy and synthetic biology. personalized immunotherapy and medicine

101 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Redirecting Immune Memory from Pathogens or Childhood Vaccines to Target Cancer VerImmune is advancing Anti-tumor Immune Redirection (AIR): A Breakthrough Therapy that Redirects Pre-Existing Immune Memory from Childhood Vaccination or Infection to Fight Cancer

188 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

The Precision Vaccines Company Belyntic creates novel vaccines for viral diseases with unmet medical need. We have developed and validated a new platform technology, that generates self-adjuvant synthetic long peptides for a safe and durable induction of cellular immunity. Drug development, Cellular immunity, and Platform technology

165 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Transforming cancer and autoimmune treatments with unique IL-1RAP targeting approaches Advesya is a pioneering and transformative biotechnology company developing therapies for difficult-to-treat cancers. Haematology & Oncology, Antibody Drug Conjugate, Cell Therapy, and Autoimmune

398 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

We build high tech equipment supporting end-to-end development and manufacture of cell and gene therapies. We build high tech equipment supporting end-to-end development and manufacture of cell and gene therapies. biotech, medtech, cell therapy, gene therapy, CAR-T, MSC, iPS, ATMP, Tissue Engineering, cell based therapies, biotherapies, RMAT, and Manufacturing

428 similar entities Tags: FrenchTech2030 Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Pan Cancer T is a biotechnology company developing T cell receptor (TCR) T-cell therapy for solid tumors. Pan Cancer T is a biotechnology spin-out (Erasmus MC, Rotterdam) focussed on the discovery and development of T cell receptor (TCR) T cell therapies. We exploit the 20 years of pioneering in adoptive T cell therapy as a springboard to breakthrough treatment of solid tumors. Pan Cancer T develops natural affinity TCR T cell therapies towards unique and proprietary intracellular targets expressed by multiple solid tumors, and make T cell therapy maximally accessible despite the tumor micro-environment challenges.

9 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Expertise in protein engineering | in silico & in vitro antibody discovery platform We work in partnership with technology platforms, pharmaceutical companies, and academic research groups to create next generation cell and molecular therapies. We integrate novel technologies into a synthetic antibody platform to provide the most advanced discovery engine possible.

259 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Science to Transform Lives Immunocore is a leading T cell receptor (TCR) biotechnology company working to create first-in-class biological therapies to address unmet patient needs in oncology as well as infectious and autoimmune diseases. See our community guidelines: http://bit.ly/2kFA8hr Biotechnology, Cancer, Oncology, Infectious Diseases, Autoimmune Diseases, T Cell Receptor, Immunotherapy, ImmTAX, ImmTAC, ImmTAV, and ImmTAAI

264 similar entities Type: Startup Activities: deeptech hrtech biotech Technologies: Synthetic Biology

a NOVARTIS company CELLforCURE gathers all cell and gene therapies activities of the LFB group. With an annual production capability of several thousands of therapeutics batches, the Les Ulis CELLforCURE facility is the first modular entity in Europe to enable large scale industrial production for ATMPs. This platform operates on a mixed model of a CDMO (Contract Development and Manufacturing Organisation) providing large scale GMP and cGMP production services, for both clinical and commercial needs, and of a pharmaceutical company leading the development of cell and gene therapies medicinal products up to their launch on the market. CELLforCURE is an …

87 similar entities Type: Startup Activities: healthtech manufacturing deeptech biotech Technologies: Synthetic Biology

New therapeutic targets based on arsenic trioxide (As2O3) Founded in 2010, MEDSENIC is a biopharmaceutical start-up that aims to exploit the new possibilities offered by the therapeutic use of arsenic trioxide (As2O3) and thereby provide a treatment for patients with autoimmune diseases. santé, biotechnologies, bioparma, biopharmaceutical, biotech, health, biotechnology, autoimmune diseases, and maladies auto-immunes

346 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Kuur is committed to transforming the lives of patients with cancer and is leading the development of off-the-shelf engineered CAR-NKT cell therapies. Our approach combines the highly differentiated, natural biology of a specific subset of T cells, called natural killer T cells (NKT cells) and innovative chimeric antigen receptor (CAR) construct engineering. In combination, this delivers a very compelling and unique platform, that we believe has the potential to produce many future therapies targeting both hematological and solid tumors. Immunotherapy, Cancer, Oncology, T cells, TCR, CAR, CAR-NKT, clinical trial, NKT Cells, celltherapy, and lifesciences

76 similar entities Type: SMB Activities: biotech deeptech transporttech Technologies: Synthetic Biology

Blue Bees Therapeutics develops immunomodulatory proteins with therapeutic potential to fight cancer Blue Bees Therapeutics is a biotechnology company founded in March 2022, dedicated to the development of first-in-class immunotherapies for the treatment of cancers, based on a breakthrough technology discovered by the team led by Dr Michel Léonetti, within the Department of Pharmacology and Immunoanalysis from CEA Paris-Saclay. This technology allows to generate antibodies stimulating the anti-tumor immune response via a double cell receptor targeting coupled with heparan sulphate proteoglycans (HSPG). Immunothérapie, Immuno-oncologie, pharma, Biotech, Immunologie, Oncologie, Cancer, Médicament, and Drug

176 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Pioneering thymus-empowered T-cell platform to fight cancer and infection Smart Immune is a clinical-stage French biotechnology company developing ProTcell, a thymus-empowered T cell progenitor platform to fully and rapidly re-arm the immune system against cancer and infection, enabling next-generation allogeneic T cell therapies. The company aims to radically improve outcomes for patients in hematology and immune-oncology. Smart Immune has ongoing collaborations with leading institutions in the US and Europe. SMART101 is in Phase I/II clinical trials in cancer patients with AML and ALL, in SCID in the EU and the US. Smart Immune is also developing therapies using gene-modified T …

57 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Automated 3D organoid screening technology We integrate standard assays on chip (eg. CRISPR, T-cell, cytotoxicity) to accelerate drug discovery from target to validation, and advance preclinical predictivity

333 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Delivering the next generation gene therapies AAVantgarde is a clinical-stage, international biotechnology company (headquartered in Italy) that has developed two proprietary adeno-associated viral (AAV) vector platforms to address the DNA cargo capacity limitations of AAV vectors Gene Therapy, Ophthalmology, and Rare diseases

338 similar entities Type: Startup Activities: healthtech biotech deeptech Technologies: Synthetic Biology

NanoMedSyn develops a new delivery platform to create first-in-class drugs by the engineering with patented AMFA vectors NanoMedSyn was born from the fundamental research of its biologist and chemist founders who discovered a breakthrough technology for drug delivery to the lysosomal cell compartment leading to potentiation of therapeutics. This technology, validated at the preclinical level, has a wide range of applications in the fields of oncology, immunity, inflammation or metabolism. NanoMedSyn’s development plan is based on a strong intellectual property of patented synthetic derivatives called AMFA. The main application is the engineering of recombinant proteins like antibodies or enzymes for …

156 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

AbLeads is a young biotech startup developing innovative solutions in Oncology, through the generation of novel, personalized therapeutic antibodies. Learn More on https://ableads.fr Biotechnology, Oncology, Immunotherapy, Therapeutic Antibodies, and Personalized Medicine

574 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Modulating T-regulatory cells to balance immunity Egle Therapeutics has been founded with a vision to become a game changer in the field of immunomodulating T-regulatory cells (Tregs) through the unique concept of Tregs’ starving while specifically targeting the most immunosuppressive ones.

185 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Discover your favorite frequencies to boost your drug discovery business CellSine provides devices and software that make advanced electrochemical impedance spectroscopy easily accessible to any microbiological researcher. It delivers a platform tool for a that enables a wide variety of biochemical studies. Biotechnology, Cell culture monitoring, Proteïn - Proteïn interactions, Suspension cultures, Receptor signaling, Biofilm maturation, and T lymphocyte activation

206 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Better technology for better health LimmaTech Biologics AG is a Swiss-based clinical stage biopharmaceutical company. We are advancing our proprietary vaccine pipeline to halt the increasing threat of global infections due to emerging antibiotic resistance (AMR) and sexually transmitted diseases. In addition to our proprietary research, we also develop vaccines together with GSK. vaccines, research & development, biotechnology, and antimicrobial resistance

147 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Designing and applying innovative technologies to dramatically expand global access to biotherapeutics. Just – Evotec Biologics, wholly owned by Evotec SE, is a first-to-industry biologics platform that leverages AI/ML technologies and world-leading molecular design, cell line development, process intensification and continuous manufacturing strategies to advance biotherapeutics from discovery through clinical stages to commercial launch. The Just – Evotec Biologics team combines deep industry experience in the fields of data, protein, process, and manufacturing sciences including automation with highly integrated and flexible capabilities to break through the scientific and economic barriers associated with the development of protein therapeutics. Our focus is …

173 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Next generation cell therapies for ALK-positive cancer patients At ALKemist Bio we are developing TCR-T cells that possess the ability to specifically target ALK antigens found on ALK-positive cancer cells, primarily focusing on non-small cell lung cancer patients. By harnessing the power of the immune system and engineering T cells to precisely recognize and combat these cancerous cells, we aim to pave the way for more effective treatments aiming at improving the standard of care. biotech, immunooncology, oncology, alkpositive, celltherapy, TCR, and ALK

119 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Actor of change Immune Biosolutions is a clinical-stage biotechnology company specializing in the discovery and engineering of avian and human antibodies for therapeutic applications. Utilizing cutting-edge technologies, we develop custom immunotherapeutic agents. Our discovery platform efficiently targets complex proteins and generate powerful, specific, and innovative antibodies. Additionally, our antibody production capability allows us to advance our own discovery programs in cancer and autoimmune diseases into the early phases of clinical development. Anticorps, Custom antibody development, Antibody, Développement sur mesure de génération d'anticorps, IgY, Chicken, Poulet, ELISA, Therapeutic Antibodies, Recombinant Antibodies, Humanized Antibodies, GPCRs, and Oncology

94 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Clinical-stage biopharmaceutical company developing transformative therapies to treat devastating human diseases Caribou Biosciences is a leading clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. Our next-generation genome-editing technology enables superior precision to develop cell therapies that are armored to potentially improve activity against diseases. We believe the future of cell therapy is off-the-shelf, and we are advancing our pipeline of off-the-shelf, or allogeneic, cell therapies from our CAR-T cell therapy platform as readily available treatments for patients with hematologic malignancies and autoimmune diseases. Next-generation CRISPR genome editing, allogeneic CAR-T cell therapies, oncology, and …

85 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Cell Signaling Technology for Organ Repair and Regeneration Cell Signaling Technology for Organ Repair and Regeneration We care for liver Our advanced therapy aims to restore liver function thanks to immunomodulatory and regenerative properties of Hepastem Cell therapy, Acquired liver diseases, Liver diseases, liver based genetic diseases, NASH, ACLF, Antibodies, Clinical stage, Chronic liver disease, Fatty liver, Acute liver disease, Regenerative medicine, Biotech, and Biotechnology

155 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Delivering the Power of T Cells to Patients with Cancer Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer. Read more about Immatics on our …

24 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

Prolonging life and increasing life quality of cancer patients through innovative immunotherapies. Learn more. Elicera Therapeutics is a clinical stage cell and gene therapy company focusing on immunooncology. The company develops CAR T-cells against both solid and liquid tumors based on its proprietary technology platform, iTANK, for a parallell activation of an innate immune response against cancer. Elicera also develops next generation oncolytic viruses with three combined mode-of-actions, applicable for treatment of most cancers. Cell and gene therapy, immunooncology, CAR T-cells, Oncolytic viruses, and immunotherapy

58 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Developing allogeneic TCR-NK therapies for solid tumors Zelluna Immunotherapy is a company pioneering the development of allogeneic T cell receptor (TCR) guided natural killer (NK) cell immunotherapies for the treatment of solid cancers. The company is developing a portfolio of tumor specific TCRs to guide NK cells with the aim to induce cancer responses that are safe, efficient and durable. For more info please visit www.zelluna.com Cancer treatment, Immunotherapy, Adoptive cell therapy, T cell receptor technologies, Immunooncology, and Solid tumors

Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

We turn blood stem cells into living drug factories At Immitra Bio, we are pioneering a next-generation gene therapy platform, harnessing Hematopoietic Stem Cells and their downstream cell lineages, such as red blood cells as living, in-vivo biotherapeutic protein factories. The CRISPR-Cas-based cell and gene therapy platform we are developing is versatile and promises to be easily reprogrammable.

221 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Cell & Gene Therapy: Automated. Scalable. Accessible Limula provides an innovative solution for the production of the most personalised cancer treatments on demand and at scale. Our product is a unique proprietary platform can perform multiple steps of cell therapy manufacturing in a single device, using end-to-end automation and integrated process analytics. Bioproduction, Immunooncology, Cell therapy, Biotechnolgoy, Manufacturing, and CAR-T

131 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Let's Build Better Cells Together We invest in our partners early on, working side by side in optimizing their processes to derisk their path to the clinic faster. Our ExPERTTM platform, which is based on our Flow Electroporation® technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATxTM, STxTM, GTxTM and VLx TM; a portfolio of proprietary related processing assemblies or disposables; and software protocols, …

313 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Pioneering immune interventions to treat chronic disease AstriVax Therapeutics is a European based, clinical-stage biopharmaceutical company, founded in 2022, that is pioneering immune interventions to treat chronic disease. The company has two prototype prophylactic assets in clinical phase and is developing its therapeutic assets to treat chronic HBV and clear high-risk HPV. AstriVax has a novel DNA-launched viral vector immunotherapy platform, Launch-iT, that is designed to create an inherent adjuvant effect to the target antigens, eliciting durable polyfunctional CD8+ and CD4+ T cell responses and robust humoral immunity. Through Launch-iT, the company has the potential to develop best-in-class immunotherapy treatments.

88 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Our R&D platform is focused on developing immune modulating therapeutics for patients with autoimmune diseases. Our immune checkpoint activators protect patient’s organ tissue. Unique approach : - Potential for BEST-in-class super agonist against immune-mediated tissue damage - High selectivity for active T-cells - Proof of concept in relevant human in vitro models and mouse model of disease

66 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Swedish biotech company exploring reprogramming as the next leap forward in cancer immunotherapy Asgard Therapeutics is a private biotech company exploring the application of direct cell reprogramming technologies for cancer immunotherapies. Formed as a spin-off from Lund University, the Company is pioneering a gene therapy approach based on its proprietary TrojanDC technology, designed to set in motion immune responses based on the biological properties of professional antigen presenting cells. Backed by Novo Holdings, Boehringer Ingelheim Venture Fund and Industrifonden, Asgard Therapeutics aims to build a pipeline of personalized cancer immunotherapies optimized to each unique patient. Cell Reprogramming, Cancer Immunotherapy, and …

147 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Treating cancer with γδ T cells | Nasdaq Ticker - $TCBP TC BioPharm is a publicly traded, clinical-stage cell therapy company developing advanced allogeneic CAR-T cell therapy products for the treatment of cancer, as well as developing gamma delta T cell therapies for the treatment of infectious disease. We have a growing team based in our Glasgow office, alongside a wide range of scientific advisors, and partner organisations. Clinical Grade Cell Therapy, Cancer Immonotherapy, Regenerative Medicine, and Stratified Medicine

208 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Unravelling immune system function, one cell at a time Cellply is a life-science company focused on developing next-generation analytical tools enabling a deep characterization cancer immunotherapies, cell therapies and cell-based biotherapeutics. Our goal is to support the development of novel cancer immunotherapies by accelerating the R&D, advancing the quality control and monitoring the clinical response to these treatments. Through the use of proprietary microfluidic technologies, highly-automated analytical instruments and AI-powered image and data analytics, the Cellply platform defines the function of the immune system one cell at a time, combining functional data with other multiplex data and providing an unprecedented …

92 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. Synthetic Biology

The Immune system under control Founded by a team with a long cutting-edge translational expertise in regulatory T cells and mechanisms of tolerance, AbolerIS Pharma is developing novel and unique therapeutic approaches to finely regulate the immune system by inducing immune tolerance and preserving useful immune responses in inflammatory, autoimmune, and degenerative diseases.

69 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Revolutionizing drug delivery HHC medical is a health tech startup developing a platform technology for targeted and non-invasive drug delivery via wireless electroporation. Drug Delivery, Genetic therapies, and Enabling life-altering therapies

408 similar entities Type: Startup Activities: deeptech healthtech biotech Technologies: Synthetic Biology

Antibody discovery engine AbCellera discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera’s engine integrates technology, data science, infrastructure, and interdisciplinary teams to solve the most challenging antibody discovery problems. AbCellera is focused on advancing an internal pipeline of first-in-class and best-in-class programs and collaborating on innovative drug development programs with partners. Antibody Discovery, Cell Culture, Antibody Therapies, Protein Analysis, Microfluidic Single Cell Analysis, Single Cell Genomics, Monoclonal Antibody Discovery, Cell Enrichment, Cell Screening, Cell Recovery, Protein engineering, T cell engagers, and Bispecifics

70 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. A.I. - Machine Learning Synthetic Biology

Innovative biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Virax Biolabs is an innovative biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. medical device development, medical device distribution, Logistics, Procurement, Distribution, IOTH, Innovation, T-Cells, and immunology

133 similar entities Type: Startup Activities: deeptech biotech healthtech Technologies: Synthetic Biology

Acquired by Evotec SE in July 2022, Rigenerand is now operating as Evotec (Moderna) Srl. Originating as a start-up from the University of Modena and Reggio Emilia developing and producing innovative products for pre-clinical and clinical applications of cell-based technologies for regenerative medicine and oncology, the cell technology company aims to fill therapeutic gaps for the many still incurable diseases by manufacturing smart treatments based on gene-modified cells with a specific focus on cancer With its team of leading cell therapy experts, Evotec (Moderna) adds a high-quality cGMP manufacturing site to the EVOcells platform increasing capacity, critical expertise, and capabilities …

125 similar entities Type: Startup Activities: manufacturing biotech deeptech Technologies: Synthetic Biology

Reinventing Cancer Immunotherapy Valo Therapeutics (ValoTx) is a developer of novel immunotherapies in cancer and infectious disease. Our unique approach to immunotherapy, based on oncolytic viruses and viral vectors combined with disease-specific peptides, delivers highly adaptable and immunogenic therapeutic vaccination platforms. A spin-out company from the University of Helsinki, Finland, Valo Tx has assembled a talented team of immunotherapy experts, who together with the founding scientists have the necessary expertise to take its patented technology through clinical development and make it available to patients. The management team has a proven track record of developing successful companies from a laboratory idea …

87 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Better Technology. Better Delivery. Developing a new generation of disease-modifying therapies. Driven by our proprietary Enhanced Delivery Oligonucleotide (EDO) platform, we are creating a pipeline of disease-modifying therapeutics with the potential to safely and effectively target the root cause of serious genetic neuromuscular and neurological disorders. Biotechnology, Chemistry, Biology, Bioscience, Life sciences, and Therapeutics

436 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Focused on the development of precisely targeted, controlled & highly active T cell therapies for cancer Autolus is a CAR T cell therapy company. We are applying our extensive programming capabilities to develop advanced autologous T cell therapies that have the potential to deliver life-changing therapies to patients with cancer and autoimmune diseases.

83 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

To make disease-modifying treatments available to patients with serious or life-threatening conditions Medibiofarma S.L is a clinical-stage biotechnology company founded in 2016 by a group of professionals with extensive experience in Drug Discovery in the pharmaceutical industry. We aim to generate innovative and high quality research programs based on the modulation of clinically validated therapeutic targets for the treatment of cancer and non-cancer diseases. Medicinal Chemistry, in vitro Pharmacology, Drug Discovery and Development, IP generation, IBD (Colitis, Crohn), Oncology, CNS, and Synaptopathies

540 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Precision Drugs against Eucaryotic Pathogens ASTRA Therapeutics is a Drug Discovery company with a mission to design and develop novel, precision engineered drugs against a whole range of Eukaryotic Pathogens.

505 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Cellestia Biotech is pioneering innovative therapeutics based on novel modes of action to treat autoimmune diseases and multi-drug resistant cancers. Our clinical stage drug candidate, CB-103, has demonstrated both safety and biological activity in humans. Along with ongoing Phase 2 IITs for multi-drug resistant cancers, CB-103 is also poised to enter a Proof-of-Concept clinical study for graft-versus-host disease (GvHD) Biopharma, Oncology, Precision Medicine, Small Molecules, Targeted Therapy, Biotech, Cancer Therapy, Transcription Factors, Autoimmune Disorders, and Inflammatory Disorders

151 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Exploiting a new class of tumour specific antigens for cancer therapy A newly established NewCo developing therapeutics targeting a novel class of tumour-specific antigen. TCR-T cells, Immuno-oncology, Vaccines, Bi-specifics, Splicing, Epigenetics, Oncology, T cell biology, and Antigen presentation

170 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Activating RNA, mastering disease Harnessing an innate mechanism of gene activation, MiNA Therapeutics'​ platform enables the development of new medicines that restore normal function to patients’ cells. We are applying our technology and clinical know-how to transform the therapy landscape of severe liver and other diseases. Gene activation, RNA therapeutics, Liver disease, and Drug discovery

213 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

TG is a biopharmaceutical company focused on the development of novel treatments for B-cell diseases. TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has completed a Phase 3 program for ublituximab, an investigational glycoengineered monoclonal antibody that targets a unique epitope on CD20-expressing B-cells, to treat patients with relapsing forms of multiple sclerosis (RMS). Biotechnology, hematological malignancies, non-Hodgkin's lymphoma, multiple sclerosis, b-cell diseases, ublituximab, and umbralisib

69 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Harnessing the power of adult stem cells to develop curative therapies for cancer and autoimmune diseases Our genetically engineered, iPSC-derived cell products are designed to specifically target hematologic and solid tumor cancers, with a broadening application to autoimmune diseases. We are leveraging our expertise in cellular reprogramming, genetic engineering, and manufacturing to develop therapies with the potential to overcome many of the challenges inherent to cell therapy and provide a significant advantage over existing cell therapy technologies. We believe our commitment to developing off-the-shelf cell therapies will expand patient access and provide an unparalleled opportunity to advance the course of …

100 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

An innovative gene editing company discovering and developing curative treatments for genetic diseases Bayer and CRISPR Therapeutics have entered into an agreement to create Casebia to discover, develop and commercialize new breakthrough therapeutics to cure blood disorders, blindness, and congenital heart disease. CRISPR Therapeutics will contribute its proprietary CRISPR-Cas9 gene-editing technology and intellectual property, while Bayer will make available its protein engineering expertise and relevant disease know-how. It is the first long-term strategic partnership of its kind to make a substantial investment in the development of target delivery systems in an effort to bring systemic in vivo CRISPR-Cas9 gene editing …

82 similar entities Type: Startup Activities: deeptech healthtech biotech Technologies: Synthetic Biology

Building the future of cell-based therapies. CAR-T is for more than just oncology. Using the full potential of gene editing, we are creating a therapeutic platform for cell based therapies that are not just disease modifying: they are curative and definitive. Cell-based Therapies and Machine Learning

118 similar entities Type: Startup Activities: biotech healthtech deeptech Technologies: Synthetic Biology SaaS A.I. Generative A.I.

Creating Tomorrow's Immunotherapies NXI therapeutics focuses on the research and development of a new generation of selective immunosuppressive drugs for autoimmune diseases and transplantations - with objectives of high efficacy, good safety without adverse effects as seen with conventional immunosuppressants.

195 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

The Cell Therapy Venture Builder MedXCell is a European cell therapy venture builder with a strong industrial mindset and a global perspective. Our focus is on technologies, techniques or novel applications in major diseases such as cancer, autoimmune, neurological and degenerative disorders. Established in 2018, we have offices in Switzerland, the EU (France) and the US (Cambridge, MA) and a multidisciplinary expert team with entrepreneurial, clinical, operational, business development and funding capabilities. Biotechnology, Cell Therapy, Immunotherapy, NK Cells, Mesenchymal Stromal Cells, Immuno-oncology, and Osteoarthritis

410 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Leading the Next Frontier of Cell Therapy Sonoma Biotherapeutics is developing engineered regulatory T cell (Treg) therapies to treat serious autoimmune and inflammatory diseases driven by an imbalanced immune system. Founded by pioneers in Treg biology and cell therapy, the company is employing proprietary platform technologies and approaches to develop a new generation of targeted Treg cell therapies designed to induce durable immune tolerance to treat and prevent autoimmune and inflammatory diseases. Sonoma Biotherapeutics is based in South San Francisco and Seattle. cell therapy and autoimmune disease

51 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Developing Innovative Cell Therapies Against Cancer Celyad Oncology is a biotechnology company focused on the discovery and development of tecnhlologies and platform for chimeric antigen receptor T cell (CAR T) therapies. Celyad Oncology was founded in 2007 and is based in Mont-Saint-Guibert, Belgium and New York, NY. The Company has received funding from the Walloon Region (Belgium) to support the advancement of its CAR T cell therapy programs. For more information, please visit www.celyad.com. Immuno-Oncology, Cancer, Immnotherapy, shRNA multiplex, and CAR T-cells

80 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Living Immunotherapies Medigene AG (FSE: MDG1) is a leading immuno-oncology platform company dedicated to developing T-cell therapies to effectively eliminate cancer. Its end-to-end technology platform is built on multiple proprietary exclusive product development and product enhancement technologies, and allows Medigene to create best-in-class differentiated, T cell receptor engineered T cell (TCR-T) therapies for multiple solid tumor indications that are optimized for both safety and efficacy. This platform provides product candidates for both its in-house therapeutics pipeline and partnering. For more information, please visit www.medigene.com Immunotherapies and T Cell receptors TCR

59 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology